



## INTERIM POSITION STATEMENT

### Mounjaro<sup>®</sup> (Tirzepatide) for managing overweight and obesity

**Recommendation:**

**Interim LSCMMG RAG status 'Do not prescribe'.**

**Tirzepatide should NOT be prescribed for managing overweight and obesity until NICE has published and a position is reached by the ICB**

The planned NICE publication date for Mounjaro<sup>®</sup> (Tirzepatide) in this indication is currently 29<sup>th</sup> May 2024.

This position statement will be reviewed within 90 days of NICE publication.